Prox1, a
C lassification of vascular endothelial tumors is often problematic and sometimes controversial. This includes subclassification of benign angiomas and determination of whether a vascular tumor is benign or malignant. Also, precise identification of angiosarcoma and differentiating it from other malignant tumors can be difficult.
Prospero homeobox 1 protein (Prox1) is an endothelial transcription factor considered a master regulator of lymphatic endothelial differentiation and expressed in the nuclei of developing and adult lymphatic endothelial cells. 9, 10, 12, 21, 30, 31 In addition, Prox1 is involved in the development of the heart, liver, and pancreas. 3, 5, 6, 26 Only limited information on Prox1 expression in vascular tumors exists to date. Kaposi sarcoma expresses Prox1 as a manifestation of lymphatic reprogramming of the neoplastic HHV8-infected endothelia. 11 Kaposiform hemangioendothelioma was recently shown to contain Prox1-positive endothelia, and Prox1 was also implicated in the pathogenesis of its invasive nature. 4, 16 One study showed the presence of Prox1 in lymphangiomas and general absence in hemangiomas, 31 and another one noted its absence in juvenile hemangiomas and lobular capillary hemangiomas. 16 There is no specific information on Prox1 in angiosarcomas.
In this study we evaluated Prox1 expression patterns in 314 vascular tumors to assess the potential of Prox1 as a diagnostic marker. We also correlated it with another lymphatic endothelial marker, podoplanin. 2, 13, 14 Also examined was CD34, a vascular endothelial marker, 27 to obtain an insight into the biology of vascular tumors. We also examined 1086 nonvascular tumors to further evaluate the specificity of Prox1 for endothelial neoplasms.
MATERIALS AND METHODS

Tissues
Selected normal developing and adult tissues and 314 vascular endothelial tumors were evaluated. Also studied for comparison were 528 nonendothelial mesenchymal tumors and 558 malignant epithelial neoplasms. Most of these tissues were arranged in multitissue blocks containing 5 to 50 cases. These blocks were generated manually by embedding rectangular tissue pieces into a single block. In the cut slides, these pieces generally yielded tissue profiles measuring 1 to 2 mm Â 2 to 4 mm, thus being larger than the round tissue profiles of 0.6 to 1 mm in tumor microarray samples and giving more tissue for analysis. A small number of cases were examined using conventional histologic slides (1 case per slide). All tissues were derived from surgical specimens.
All angiosarcomas were verified as CD31 positive and Kaposi sarcomas as HHV8 positive. Previous data on CD31 were available on most hemangioendotheliomas and hemangiomas showing positivity in the neoplastic/ lesional endothelial components.
Immunohistochemistry
A Prox1 polyclonal rabbit antibody from Angiobio (Delmar, CA) was used at a dilution of 1:250. Immunostaining was performed in a Leica Bond-Max automated immunostainer (Leica Microsystems, Bannockburn, IL). Heat-induced epitope retrieval was performed for 30 minutes using a Bond-Max high-pH epitope-retrieval buffer. Primary antibody was applied for 30 minutes, followed by Bond-Max polymer for 15 minutes. Diaminobenzidine was used as the chromogen, followed by a light hematoxylin counterstain.
The percentage of positive tumor cell nuclei was estimated. Because our preliminary experience showed reduced Prox1 immunoreactivity in old stored slides, the studies were, with few exceptions, conducted on freshly cut slides.
Only nuclear staining was considered positive. Isolated randomly, often weakly, labeled nuclei (generally <1%) were not counted as positive, because similar labeling was occasionally seen in negative controls with no primary antibody. The presence of an internal control (positive lymphatic endothelia) was considered to validate the immunostaining in any particular tissue. However, this was not universally required, as many tissues lacked lymphatics.
Immunostaining for CD34 (QBEND/10 1:150, Leica Microsystems) and podoplanin (D2-40; 1:100, Covance, Princeton, NJ) was performed on vascular endothelial tumors to obtain additional objective parameters of endothelial differentiation for comparison. These studies were conducted using similar technology as described above, with the exceptions that a low-pH epitope-retrieval buffer was used for podoplanin and epitope retrieval time for both markers was 20 minutes. Each marker was evaluated independently without knowledge of other results.
RESULTS
The results on Prox1 immunoreactivity in 314 vascular endothelial cell tumors, 528 nonendothelial, mesenchymal, and lymphohematopoietic tumors, and 558 malignant epithelial neoplasms are summarized in Tables 1 to 3 .
Developing Human Tissues
In the early first-trimester embryo, Prox1 immunoreactivity was detected in a large thin-walled body cavityassociated vascular structure consistent with the thoracic duct ( Fig. 1A) . Vascular positivity was also present in a heart-associated great vessel but not in other truncal or placental vessels. No vessels were distinguishable in the peripheral mesenchyme. However, isolated Prox1-positive nuclei were detected in the latter. Hepatocytes were moderately positive, and nuclear positivity was present in the cardiac muscle ( Fig. 1B) . Yolk sac epithelia also showed nuclear positivity (Fig. 1C ). Truncal paraspinal neural tissue and pulmonary and intestinal primordia (identified on the basis of the content of thyroid transcription factor 1-positive and CDX2-positive epithelia) were negative.
In a late first-trimester fetus, Prox1-positive small caliber vessels with attenuated endothelial cells, consistent with lymphatic vessels, were present in soft tissues of limbs ( Fig. 1D ). No immunoreactivity was detected in the liver and kidney (heart unavailable).
Non-neoplastic Adult Tissues
Lymphatic vascular endothelia in various tissues, such as skin, subcutaneous and omental fat, tonsil, periphery of lymph nodes, parotid gland periductally, gastrointestinal mucosae, urinary bladder submucosa, and uterine cervix, were highlighted as Prox1 positive. Capillary and larger vessel endothelia, neovascular endothelia of carcinomas, and pericytes were negative.
Other Prox1-positive elements included scattered epithelial cells in gastric mucosa, small numbers of epithelial cells on the intestinal crypt bottom, and pancreatic parenchymal cells. Regenerative bile ducts adjacent to hepatocellular carcinoma were sometimes positive. However, Prox1 was not detected in adult bile ducts or hepatocytes. Hypertrophic cardiac myocyte nuclei in an explanted heart were variably positive.
Lymphoid tissue in lymph nodes and tonsil, squamous cell epithelia, respiratory and glandular epithelia in the nose and gastrointestinal tract, urothelia, renal epithelia, hepatocytes, adipose tissue, vascular and visceral smooth muscle, and skeletal muscle were negative.
Benign Vascular Endothelial Tumors
All lymphangiomas including examples from the skin and subcutis, abdomen, and a cystic lymphangioma from the neck showed extensive Prox1 positivity in the lining endothelia ( Fig. 2A ), which were also positive for podoplanin. A cutaneous lymphangioendothelioma showed focal positivity in 15% of tumor endothelia.
Among hemangiomas, most consistent positivity was seen in the endothelia of spindle cell hemangiomas (16 of 17 cases), whereas the interstitial spindle cells were negative ( Fig. 2B ). All but 2 of 10 spindle cell hemangiomas also had podoplanin-positive endothelia, and the endothelia were CD34 positive in all cases.
A majority of large caliber vessels of venous hemangioma with irregular smooth muscle cells (6 of 8) were lined by Prox1-positive endothelial cells Fig. 2C ). These cases also had CD34-positive endothelia, whereas only 3 of 7 were podoplanin positive.
Although most capillary hemangiomas, other than juvenile and lobular capillary ones, were Prox1 negative, 2 cases showed variable Prox1 positivity in the lining endothelia. These two capillary hemangiomas were CD34 and podoplanin-positive. The latter marker also labeled one Prox1-negative example.
Cavernous hemangiomas were generally Prox1 negative. However, in some hepatic examples, Prox1positive and podoplanin-positive lymphatic vessels were present within the septa of the cavernous spaces ( Fig. 2D ). In addition, 2 cavernous hemangiomas contained 10% and 60% of Prox1-positive endothelia, and 1 of these also had podoplanin positivity, which was detected in an additional Prox1-negative case. All juvenile and lobular capillary hemangiomas were Prox1 negative, with the exception of occasional small caliber lymphatic vessels with positive endothelia.
Hemangioendotheliomas
Dabska-type angioendothelioma (papillary intralymphatic angioendothelioma) contained Prox1-positive endothelia in the vascular pseudorosette formations (Fig. 3A) . Retiform hemangioendotheliomas were almost always strongly Prox1 positive (Fig. 3B ). All but 2 of these cases were also positive for podoplanin. CD34 was detected in 4 of 8 cases studied.
Epithelioid hemangioendotheliomas (almost all from peripheral soft tissue) were heterogenous: almost half of them (29 of 62) contained Prox1-positive neoplastic cells, with the majority of tumor cells being labeled in positive cases (Fig. 3C ). There was a positive correlation between Prox1 and podoplanin status. Of the Prox1-positive cases, 11 of 15 (73%) were also podoplanin positive, whereas only 3 of 28 (11%) of Prox1-negative cases were podoplanin positive. However, CD34 positivity was approximately similar in both Prox1positive and Prox1-negative cases: 6 of 14 (43%) and 13 of 24 (54%), respectively. One epithelioid sarcoma-like hemangioendothelioma was Prox1 negative.
Kaposiform hemangioendotheliomas contained a prominent Prox1-positive endothelial component, whereas the spindle cells corresponding to the pericytic population were negative (Fig. 3D) . The endothelial component further examined in 3 cases was also positive for both CD34 and podoplanin.
Angiosarcomas and Kaposi Sarcoma
The results are summarized in Table 1 . Angiosarcomas showed variable Prox1 nuclear labeling, and overall 53 of 105 cases (50%) were positive. All but 4 cases had a fraction of 20% or more tumor cells positive. A considerable majority of cutaneous angiosarcomas from the head and neck and extremities were positive (23 of 28, 82%), as were the majority of radiation-induced angiosarcomas of the chest wall and breast. Less commonly positive were angiosarcomas of deep tissue and viscera. Prox1 was equally detected in vasoformative and poorly differentiated solid angiosarcomas. As noted with other transcription factors, mitotic nuclei were generally negative (Figs. 4A-C). Of the epithelioid angiosarcomas, 7 of 12 (58%) were Prox1 positive.
There was an inverse correlation between Prox1 positivity and CD34 status: Of Prox1-positive angiosarcomas, 20 of 46 (43%) were CD34 positive, whereas Prox1-negative angiosarcomas were nearly twice as often CD34 positive: 39 of 52 (75%).
There was a positive correlation between Prox1 and podoplanin immunoreactivity. Most Prox1-positive angiosarcomas were also positive for podoplanin (43 of 52, 83%), whereas only a few Prox1-negative angiosarcomas were positive (11 of 56, 20%). However, because of extensive nonendothelial labeling of podoplanin in submesothelial and stromal elements, some angiosarcomas were uninterpretable for podoplanin. Compared with Prox1, podoplanin identified a greater percentage of tumor cells in some angiosarcomas; only 1 positive case showed <50% of tumor cells positive, and overall 55 angiosarcomas were podoplanin positive. All but 1 Kaposi sarcoma were Prox1 positive (Fig. 4D) .
Nonendothelial Mesenchymal and Hematopoietic Tumors
All nonendothelial vascular tumors including soft tissue hemangiopericytomas, glomus tumors, and cerebellar hemangioblastomas were negative for Prox1 ( Table 2) .
Among mesenchymal nonendothelial tumors, Prox1 positivity was detected in the epithelia of some biphasic synovial sarcomas (Fig. 5A) , whereas monophasic tumors were negative. Four of 16 Ewing sarcomas and 5 of 15 retroperitoneal paragangliomas also contained Prox1positive tumor cells ( Fig. 5B ). Prox1 was not detected in any undifferentiated sarcomas, chordomas, gastrointestinal stromal tumors, leiomyosarcomas, malignant peripheral nerve sheath tumors, melanomas, and small and large cell B-cell lymphomas. 
Malignant Epithelial Neoplasms
Prox1-positive tumor cells were detected in 55 of 558 carcinomas of various types (Table 3 ). Most commonly positive were intrahepatic cholangiocarcinoma (10 of 15) ( Fig. 5C ), colorectal carcinoma (18 of 38), and pulmonary small cell carcinoma (5 of 12) (Fig. 5D ), each of which typically showed heterogenous positivity. Less commonly, Prox1 positivity was detected in hepatocellular carcinoma (4 of 25), pulmonary adenocarcinoma (4 of 31), prostate carcinoma (2 of 51), and ductal carcinoma of the breast (1 of 49). No Prox1-positive tumor cells were detected in papillary thyroid carcinomas, squamous cell carcinomas, pancreatic adenocarcinomas, renal cell carcinomas, and seminomas.
DISCUSSION
In this study, we immunohistochemically examined the expression of Prox1 protein, encoded by the corresponding prospero homeobox 1 (PROX1) gene in a broad range of tumors, especially the vascular ones.
Prox1 is known to be expressed in lymphatic endothelium and is important in the programming and maintenance of its differentiation. 9, 10, 30, 31 Its haploinsufficiency promotes lymphatic vascular defects and is associated with adultonset obesity. 8 Prox1 is also expressed in some epithelial tissues, notably liver and pancreas, especially during development. 5, 6 In this study, we were able to replicate previously known patterns of Prox1 expression in normal tissues, indicating that sufficient proficiency of Prox1 detection can be obtained in routinely processed formalin-fixed and paraffin-embedded tissue with the antibody used.
Prox1 is consistently expressed in lymphatic endothelium and lymphangiomas, in agreement with previous observations. 31 In general, Prox1 is not present in either juvenile or adult capillary or cavernous hemangiomas, and its expression correlates fairly well with that of podoplanin. Previous studies have also demonstrated a lack of LYVE-1, another lymphatic endothelial marker, in juvenile hemangiomas. 22 However, a small subset of capillary and cavernous hemangiomas is Prox1 positive. Venous hemangiomas, consisting of larger vascular profiles with irregular smooth muscle lining, often show endothelial Prox1 expression. This could possibly be related to the observation that subsets of lymphatics originate from veins. 31 Further studies are needed to determine whether there is any clinical correlation with this observation. It remains to be determined whether Prox1 contributes to clinicopathologic distinction between hemangioma and vascular malformation, a prominent trend in pediatric surgery and pathology. 17 In this study, a lack of clinical correlation did not allow further examination of this issue.
Spindle cell hemangioma is an unusual hemangioma variant usually occurring in peripheral extremity sites, sometimes associated with vascular syndromes, such as the Klipper-Trenaunau syndrome and the Maffucci syndrome. 24 In this study we demonstrated consistent Prox1-expression in endothelia, paralleling podoplanin expression and indicating a lymphatic endothelial-like phenotype.
Retiform hemangioendothelioma, a low-grade cutaneous-subcutaneous vascular tumor, was consistently positive for Prox1. These tumors also expressed podoplanin, another lymphoid vascular determinant, indicating lymphatic-like vascular differentiation. Podoplanin was previously reported in retiform hemangioendothelioma. 18 Similarly, Prox1 is also expressed in papillary intralymphatic angioendothelioma (Dabska tumor), previously known to express vascular endothelial growth factor 3, another lymphatic vascular determinant. 7 Epithelioid hemangioendotheliomas were heterogeneous for Prox1 expression, with approximately half of them being positive. The positive cases were typically also positive for podoplanin, supporting lymphatic endothelial-like differentiation. It remains to be seen whether clinicopathologic studies reveal any correlation with the Prox1 status in these tumors. Angiosarcomas commonly express Prox1, and this is especially true for cutaneous angiosarcomas. A great majority of angiosarcomas of the scalp and face and peripheral cutaneous sites were positive, along with a majority of radiation-associated cutaneous angiosarcomas of the chest wall and breast. Prox1 positivity correlated strongly with podoplanin positivity, supporting lymphatic vessel-like phenotypic features, as also previously shown on the basis of podoplanin 13 and vascular endothelial growth factor receptor 3 expression 23 in a subset of angiosarcomas. The common expression of Prox1 indicates that this marker is useful in the identification of angiosarcomas. However, Prox1 does not separate benign and malignant vascular tumors, as subsets of both can be positive.
Kaposi sarcomas are also consistently Prox1 positive, and therefore additional markers, such as HHV8, and observation of morphologic differences are necessary to separate it from angiosarcoma. Prox1 expression in Kaposi sarcoma is also paralleled by expression of other lymphatic endothelial markers, such as podoplanin and vascular endothelial growth factor receptor 3. 29 The relative rarity of Prox1 expression in mesenchymal mimics of angiosarcoma, such as metastatic melanoma, undifferentiated sarcomas, and sarcomatoid carcinomas, makes Prox1 a fairly specific endothelial marker. However, Prox1 expression in synovial sarcoma, Ewing sarcoma, paraganglioma, and a significant subset of carcinomas, especially cholangiocarcinoma, intestinal carcinomas, and neuroendocrine carcinomas, and, to a lesser degree, other carcinomas, has to be considered in the differential diagnosis.
The expression of Prox1 in cholangiocarcinomas, hepatocellular carcinomas, and pancreatic endocrine tumors seems to parallel the Prox1 expression in the developing liver and pancreas, indicating oncofetal-like expression. Further studies are necessary to determine whether the Prox1-positive carcinomas of the gastrointestinal tract and liver and elsewhere are clinicopathologically distinctive. The same applies to Prox1-positive subsets of paragangliomas, Ewing sarcomas, and synovial sarcomas. The biological role of Prox1 in carcinomas seems to be complex. Two studies indicate that Prox1 may be a tumor suppressor protein specifically lost in breast cancer and cholangiocarcinoma progression by genetic or epigenetic mechanisms. 15, 28 In contrast, Prox1 has also been identified as an oncogenic factor related to progression of colon cancer. 25 Compared with panendothelial markers CD31, Etsrelated transcription factor (ERG), and claudin-5, Prox1 is less sensitive in the comprehensive identification of angiosarcomas because of its restricted reactivity with the lymphatic-like endothelial phenotype. 19, 20 However, compared with podoplanin, another marker of the lymphatic endothelial phenotype, 1, 2, 13 Prox1 expression is sometimes easier to interpret, as podoplanin immunoreacitivity is often additionally present in nonendothelial components such as mesothelial, submesothelial, and some nonendothelial mesenchymal cells. 14 However, Prox1 may be slightly less sensitive than podoplanin, as it identifies a smaller number of tumors and often also a smaller fraction of cells in vascular tumors, especially angiosarcomas.
In conclusion, we examined Prox1 expression in a large number of vascular endothelial and nonendothelial neoplasms. Prox1 is consistently present in lymphangiomas, spindle cell and venous hemangiomas, retiform and Kaposiform hemangioendothelioma, and Kaposi sarcoma. In addition, it is expressed in a majority of cutaneous angiosarcomas while being less commonly expressed in visceral angiosarcomas and in a half of epithelioid hemangioendotheliomas. Prox1 expression correlates strongly with podoplanin expression and represents a marker of lymphatic endothelial-like differentiation. Prox1 is a useful marker in the identification of subsets of vascular endothelial tumors in studying the biology of vascular tumors. However, Prox1 expression in some carcinomas and sarcomas and paragangliomas has to be considered when applying it as an endothelial marker.
